AnaptysBio, Inc. has suffered a series of setbacks in the clinic with imsidolimab but its success in a late-stage trial for a rare but potentially life-threatening form of psoriasis could, it hopes, lead to a lucrative licensing deal.
Key Takeaways
- AnaptysBio's imsidolimab will be filed next year for generalized pustular psoriasis
- However, the company is looking to out-license the drug to concentrate on rosnilimab for rheumatoid arthritis
- The IL-36R therapy
The San Diego, CA-based firm has unveiled positive topline data from the Phase III GEMINI-1 trial evaluating imsidolimab in patients with generalized pustular psoriasis (GPP) flares
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?